The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
telephone:
0141 330 3509
email:
Krishna.Yalla@glasgow.ac.uk
Room 329, Translational Pharmacology Laboratory, Wolfson Wohl Cancer Research Centre, Switchback Road, Garscube Estate, Glasgow, G61 1QH
Gallagher, P. F. et al. (2022) A CRUK First-in-human Phase I Trial of LY3143921, a Novel CDC7 Inhibitor, in OPatients with Advanced Solid Tumors. 2022 ASCO Annual Meeting I, 03-07 Jun 2022. p. 3103. (doi: 10.1200/JCO.2022.40.16_suppl.3103)
Salomé, M. , Magee, A., Yalla, K., Chaudhury, S. , Sarrou, E. , Carmody, R. J. and Keeshan, K. (2018) A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling. Cell Death and Disease, 9(5), 443. (doi: 10.1038/s41419-018-0467-3) (PMID:29670085) (PMCID:PMC5906628)
O'Connor, C., Yalla, K., Salome, M. , Moka, H. A., Gómez Castañeda, E., Eyers, P. A. and Keeshan, K. (2018) Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2. Oncotarget, 9(19), pp. 14977-14992. (doi: 10.18632/oncotarget.24525) (PMID:29599919) (PMCID:PMC5871090)
Yalla, K. et al. (2018) FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Molecular Psychiatry, 23(5), pp. 1278-1286. (doi: 10.1038/mp.2017.138) (PMID:28727686) (PMCID:PMC5984089)
Yalla, K., O'Connor, C., Campos, J. and Keeshan, K. (2016) TRIB2 Transformed GMP is the Myeloid Leukaemia Initiating Cell. 21st Congress Of The European Hematology Association, Copenhagen, Denmark, 9-12 June 2016.
Tankou, S. et al. (2016) SUMOylation of DISC1: a potential role in neural progenitor proliferation in the developing cortex. Molecular Neuropsychiatry, 2(1), pp. 20-27. (doi: 10.1159/000444257) (PMID:27525255) (PMCID:PMC4979612)
Sheppard, C. L. et al. (2014) Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression. Cellular Signalling, 26(9), pp. 1958-1974. (doi: 10.1016/j.cellsig.2014.04.023)
Cameron, R.T., Coleman, R.G., Day, J.P., Yalla, K.C., Houslay, M.D., Adams, D.R., Shoichet, B.K. and Baillie, G.S. (2013) Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochemical Pharmacology, 85(9), pp. 1297-1305. (doi: 10.1016/j.bcp.2013.02.026) (PMID:23473803) (PMCID:PMC3625111)
Ritchie, S. A., Kohlhaas, C. F., Boyd, A. R., Yalla, K. C., Walsh, K., Connell, J. M.C. and Salt, I. P. (2010) Insulin-stimulated phosphorylation of endothelial nitric oxide synthase at serine-615 contributes to nitric oxide synthesis. Biochemical Journal, 426(1), pp. 85-90. (doi: 10.1042/BJ20091580)
Salomé, M. , Magee, A., Yalla, K., Chaudhury, S. , Sarrou, E. , Carmody, R. J. and Keeshan, K. (2018) A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling. Cell Death and Disease, 9(5), 443. (doi: 10.1038/s41419-018-0467-3) (PMID:29670085) (PMCID:PMC5906628)
O'Connor, C., Yalla, K., Salome, M. , Moka, H. A., Gómez Castañeda, E., Eyers, P. A. and Keeshan, K. (2018) Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2. Oncotarget, 9(19), pp. 14977-14992. (doi: 10.18632/oncotarget.24525) (PMID:29599919) (PMCID:PMC5871090)
Yalla, K. et al. (2018) FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Molecular Psychiatry, 23(5), pp. 1278-1286. (doi: 10.1038/mp.2017.138) (PMID:28727686) (PMCID:PMC5984089)
Tankou, S. et al. (2016) SUMOylation of DISC1: a potential role in neural progenitor proliferation in the developing cortex. Molecular Neuropsychiatry, 2(1), pp. 20-27. (doi: 10.1159/000444257) (PMID:27525255) (PMCID:PMC4979612)
Sheppard, C. L. et al. (2014) Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression. Cellular Signalling, 26(9), pp. 1958-1974. (doi: 10.1016/j.cellsig.2014.04.023)
Cameron, R.T., Coleman, R.G., Day, J.P., Yalla, K.C., Houslay, M.D., Adams, D.R., Shoichet, B.K. and Baillie, G.S. (2013) Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochemical Pharmacology, 85(9), pp. 1297-1305. (doi: 10.1016/j.bcp.2013.02.026) (PMID:23473803) (PMCID:PMC3625111)
Ritchie, S. A., Kohlhaas, C. F., Boyd, A. R., Yalla, K. C., Walsh, K., Connell, J. M.C. and Salt, I. P. (2010) Insulin-stimulated phosphorylation of endothelial nitric oxide synthase at serine-615 contributes to nitric oxide synthesis. Biochemical Journal, 426(1), pp. 85-90. (doi: 10.1042/BJ20091580)
Gallagher, P. F. et al. (2022) A CRUK First-in-human Phase I Trial of LY3143921, a Novel CDC7 Inhibitor, in OPatients with Advanced Solid Tumors. 2022 ASCO Annual Meeting I, 03-07 Jun 2022. p. 3103. (doi: 10.1200/JCO.2022.40.16_suppl.3103)
Yalla, K., O'Connor, C., Campos, J. and Keeshan, K. (2016) TRIB2 Transformed GMP is the Myeloid Leukaemia Initiating Cell. 21st Congress Of The European Hematology Association, Copenhagen, Denmark, 9-12 June 2016.